Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers
Contact
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers

Daily Archives: February 5, 2019

Sensei Biotherapeutics to Present at BIO CEO & Investor Conference

Press ReleaseBy Sensei TeamFebruary 5, 2019

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc.., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the BIO CEO & …

© 2021 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top